UBS Group’s Novo Nordisk A/S (B Shares) ADRhedged NVOH Stock Holding History

UBS Group’s Portfolio NVOH Stock Details NVOH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$206	Buy	+10	New	+$256	﹤0.01%	10029
2025 Q4	–	Sell	-81	Closed	-$2.44K	–	11435
2025 Q3	$2.44K	Sell	81 -254	-76%	-$8.05K	﹤0.01%	9173
2025 Q2	$12.2K	Hold	335	–	–	﹤0.01%	8744
2025 Q1	$13.4K	Buy	+335	New	+$16.1K	﹤0.01%	8462

UBS Group's NVOH Position: Q1 2026 in Review

UBS Group opened a new position in Novo Nordisk A/S (B Shares) ADRhedged (NVOH) in Q1 2026: 10 shares worth $206. The stake represents ﹤0.01% of the portfolio and ranks #10029 among its holdings. This is a return to the name: UBS Group previously reported a position in NVOH as recently as Q3 2025.

UBS Group first reported a position in NVOH in Q1 2025 and has held it in 4 quarters since. The position peaked at $13.4K in Q1 2025. 1 fund tracked by Wall St. Rank holds NVOH as of Q1 2026.

UBS Group held 10 shares of Novo Nordisk A/S (B Shares) ADRhedged worth $206 as of Q1 2026.
Novo Nordisk A/S (B Shares) ADRhedged was a new UBS Group position in Q1 2026.
Novo Nordisk A/S (B Shares) ADRhedged made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10029 holding.
UBS Group first reported a position in Novo Nordisk A/S (B Shares) ADRhedged in Q1 2025 and has held it in 4 quarters since.
UBS Group's Novo Nordisk A/S (B Shares) ADRhedged position peaked at $13.4K in Q1 2025.
1 fund tracked by Wall St. Rank held Novo Nordisk A/S (B Shares) ADRhedged as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.